Using Steroids in DME Treatment

EP: 1.Navigating Step Therapy in nAMD and DME

EP: 2.Role of Biosimilars in nAMD and DME Step Therapy

EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg

EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice

EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME

EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies

Now Viewing

EP: 7.Using Steroids in DME Treatment

EP: 8.Patient Selection for New nAMD and DME Therapies

EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg

EP: 10.Safety Considerations for New Therapies

EP: 11.Promoting Treatment Adherence in nAMD and DME

Summary

Experts discuss the use of steroids in the treatment of diabetic macular edema (DME). They agree that steroids can be beneficial in DME due to its inflammatory nature, especially in patients with persistent fluid despite anti-VEGF treatment. However, they note that steroids are often added later in the treatment course in the United States compared to other countries like Italy and Japan. The physicians acknowledge the potential adverse effects of steroids, such as cataract formation and increased intraocular pressure, particularly in younger patients. Despite these risks, they emphasize the importance of considering steroids earlier in the treatment regimen for DME patients, especially in non-pseudophakic patients, as steroids can target a broader range of cytokines beyond VEGF. They both express support for the use of steroids in diabetic retinopathy or DME, while noting that steroids are not indicated for age-related macular degeneration (nAMD).

This summary was AI-generated and edited for clarity.